Natera Inc (NTRA) was Reiterated by The Benchmark Company to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 15 from a previous price target of $14 . The Benchmark Company advised their investors in a research report released on May 11, 2016.
Many Wall Street Analysts have commented on Natera Inc. The Benchmark Company Initiated Natera Inc on Apr 19, 2016 to “Buy”, Price Target of the shares are set at $14.
On the company’s financial health, Natera Inc reported $-0.17 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on May 10, 2016. Analyst had a consensus of $-0.46. The company had revenue of $61.90 million for the quarter, compared to analysts expectations of $49.74 million. The company’s revenue was up 30.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.89 EPS.
Natera Inc closed down -0.36 points or -3.59% at $9.68 with 1,99,737 shares getting traded on Tuesday. Post opening the session at $10.01, the shares hit an intraday low of $9.56 and an intraday high of $10.01 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Feb 3, 2016, Jonathan Sheena (Chief Technology Officer) sold 10,000 shares at $8.03 per share price. According to the SEC, on Jan 5, 2016, Matthew Rabinowitz (CEO, President) sold 54,683 shares at $10.22 per share price. On Jul 9, 2015, James Healy (director) purchased 350,000 shares at $18.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Natera Inc. is a diagnostics company. The Company has molecular and bioinformatics technology that it deploys to change genetic diseases across the world. Its molecular assays measure various regions across the genome from samples as small as a single cell. Its statistical algorithms combine these measurements with the available data to detect a range of serious conditions. It is engaged in developing products for various oncology applications. In addition to its direct sales force in the United States the Company has a global network of over 70 laboratory and distribution partners. It has introduced a cloud-based distribution model. It also has launched seven molecular diagnostic tests. The Company launched Panorama which is its non-invasive prenatal test (NIPT). Its products include Pre-implantation Genetic Screening Pre-implantation Genetic Diagnosis Products of Conception Non-Invasive Paternity Testing High Throughput Carrier Screening and Non-Invasive Prenatal Testing.